Yuan Hejia, Li Yongwei, Wu Jitao, Zhao Yining, Feng Fan, Zhao Hongwei, Yu Guohua, Peng Peng
Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong, 264000, China.
Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Prostate Int. 2025 Jun;13(2):96-102. doi: 10.1016/j.prnil.2024.11.008. Epub 2024 Nov 30.
The purpose of this study is to comprehensively analyze cases of primary diffuse large B-cell lymphoma of the prostate (P-DLBCL-P) from a global perspective, aiming to understand the disease's characteristics, treatment responses, and outcomes. By doing so, we seek to establish a valuable reference for the clinical management of this rare malignancy.
This study conducted a retrospective review of P-DLBCL-P cases reported worldwide, using various online databases, including PubMed, Scopus, and other English databases, as well as WanFang Data and China National Knowledge Infrastructure in Chinese, collecting clinical pathology information, treatment modalities, and prognosis of patients, and conducted survival analysis using the Kaplan-Meier method.
A cohort comprising 68 patients was enrolled in this study. Lower urinary tract symptoms were prevalent in 90.63% of cases. Furthermore, 89.5% of patients exhibited prostate-specific antigen levels below the threshold of 4 ng/mL. Prostate biopsy was the most commonly used method, accounting for 52.38% of cases, followed by transurethral resection of the prostate at 33.33%. Approximately 33.90% of patients diagnosed with prostate lymphoma experienced stage IV disease, with the bladder or ureter being the organs most frequently involved (53.33%). Surgical procedures were associated with an elevated risk of uncontrollable hemorrhage. Notably, chemotherapy demonstrated a positive therapeutic response, resulting in a complete remission rate of 50.94% and a partial remission rate of 28.30%. A subsequent follow-up study revealed a 1-year survival rate of 73.08% and a 3-year survival rate of 65.38%.
The symptoms of P-DLBCL-P are often atypical, leading to many patients being diagnosed at a later stage of the disease. Through a global study of cases, we have confirmed the efficacy of the rituximab-cyclophosphamide-adriamycin-vincristine-prednisone regimen as the preferred treatment option. Surgical intervention is typically only used for diagnostic purposes or to relieve organ obstruction.
本研究旨在从全球视角全面分析原发性前列腺弥漫性大B细胞淋巴瘤（P-DLBCL-P）病例，以了解该疾病的特征、治疗反应及预后。通过这样做，我们旨在为这种罕见恶性肿瘤的临床管理建立有价值的参考。
本研究对全球范围内报道的P-DLBCL-P病例进行了回顾性分析，使用了多个在线数据库，包括PubMed数据库、Scopus数据库及其他英文数据库，以及万方数据和中国知网等中文数据库，收集患者的临床病理信息、治疗方式及预后情况，并采用Kaplan-Meier法进行生存分析。
本研究纳入了68例患者。90.63%的病例存在下尿路症状。此外，89.5%的患者前列腺特异性抗原水平低于4 ng/mL的阈值。前列腺活检是最常用的方法，占病例的52.38%，其次是经尿道前列腺切除术，占33.33%。约33.90%诊断为前列腺淋巴瘤的患者处于IV期疾病，膀胱或输尿管是最常受累的器官（53.33%）。手术操作与不可控制出血的风险增加相关。值得注意的是，化疗显示出积极的治疗反应，完全缓解率为50.94%，部分缓解率为28.30%。随后的随访研究显示，1年生存率为73.08%，3年生存率为65.38%。
P-DLBCL-P的症状通常不典型，导致许多患者在疾病晚期才被诊断出来。通过对病例的全球研究，我们证实了利妥昔单抗-环磷酰胺-阿霉素-长春新碱-泼尼松方案作为首选治疗方案的疗效。手术干预通常仅用于诊断目的或缓解器官梗阻。
